Summary

Relates to preserving access to affordable drugs; provides that an agreement resolving or settling, on a final or interim basis, a patent infringement claim, in connection with the sale of a pharmaceutical product, shall be presumed to have anticompetitive effects if a nonreference drug filer receives anything of value from another company asserting patent infringement and if the nonreference drug filer agrees to limit or forego research, development, manufacturing, marketing, or sales of the nonreference drug filer's product for any period of time.

Digest published by the state legislature, retrieved via Open States. Heard is not affiliated with either.

Bill text

The full text of this bill isn't on Heard yet. The official documents are linked below.

• A8576Official document (HTML)
• A8576Official document (PDF)

No roll-call votes recorded for this bill yet.